Cell Signaling Technology

Product Pathways - Neuroscience

RGS4 Antibody #9195

Applications Reactivity Sensitivity MW (kDa) Source
W IP H M R Endogenous 23 Rabbit

Applications Key:  W=Western Blotting  IP=Immunoprecipitation
Reactivity Key:  H=Human  M=Mouse  R=Rat
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

RGS4 Antibody recognizes endogenous levels of total RGS4 protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Cys33 of human RGS4 protein. Antibodies are purified by protein A and peptide affinity chromatography.

Western Blotting

Western Blotting

Western blot analysis of extracts from various cell lines using RGS4 Antibody.

Western Blotting

Western Blotting

Western blot analysis of extracts from SH-SY5Y cells, untreated (-) or treated (+) with DAMGO (1 μM, 16 hr), using RGS4 Antibody and β-Actin (13E5) Rabbit mAb #4970.

Background

Regulators of G protein signaling (RGS) are a family of about 40 proteins that determine the signaling amplitude and duration of G protein-coupled receptor signaling via modulation of the GTPase activity of G proteins (1-3). Each RGS has a distinct structure, expression pattern, and regulation, resulting in preferential interactions with receptors, G proteins, and other signaling proteins, as well as a unique function (4).

RGS4 is a small RGS of 23 kDa that belongs to the R4 subfamily of RGS. It harbors a short N-terminus thought to be critical for its functional specificity towards GPCRs and a RGS homology domain (RH domain) (5). RGS4 shares activity at both Gαq (6) and Gαi/o proteins (7).RGS4 degradation is regulated by opioid receptor-mediated ubiquitination after stimulation by opioid receptor agonists such as DAMGO (8); and RGS4 modulates the action of morphine and other opiates in vivo (9).

  1. Hollinger, S. and Hepler, J.R. (2002) Pharmacol Rev 54, 527-59.
  2. Traynor, J.R. and Neubig, R.R. (2005) Mol Interv 5, 30-41.
  3. Neubig, R.R. and Siderovski, D.P. (2002) Nat Rev Drug Discov 1, 187-97.
  4. Terzi, D. et al. (2009) Prog Mol Biol Transl Sci 86, 299-333.
  5. Hollinger, S. and Hepler, J.R. (2002) Pharmacol Rev 54, 527-59.
  6. Xu, X. et al. (1999) J Biol Chem 274, 3549-56.
  7. Berman, D.M. et al. (1996) Cell 86, 445-52.
  8. Wang, Q. and Traynor, J.R. (2011) J Biol Chem 286, 7854-64.
  9. Han, M.H. et al. (2010) Biol Psychiatry 67, 761-9.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products